Literature DB >> 23031763

Hepaticocholecystoenterostomy as an alternative to hepaticojejunostomy for biliary bypass.

J Gani1, K Lewis.   

Abstract

INTRODUCTION: Hepaticojejunostomy is the standard biliary bypass technique for periampullary cancer when trial dissection reveals unresectable disease or endoscopic stent placement is not possible. This anastomosis can be technically demanding and potentially difficult. The simpler technique of hepaticocholecystoenterostomy (HCE) has only previously been reported in very limited numbers and without outcome data.
METHODS: All patients undergoing HCE for the management of periampullary cancer were identified from a prospectively maintained computerised database of a single surgeon and were reviewed retrospectively. The HCE technique achieves a biliary bypass by two anastomoses, using the gallbladder as a conduit. It involves an anastomosis of the infundibulum of the gallbladder to the common hepatic duct followed by a second anastomosis of the gallbladder fundus to the proximal small bowel.
RESULTS: From 1996 to 2010, 30 patients with pancreatic adenocarcinoma required a biliary bypass after a failed trial of Whipple procedure (80%) or failed endoscopic stenting (20%). There were 19 men and 11 women with a mean age of 64.5 years. The mean operative time for HCE alone was 92 minutes. The mean length of hospital stay was nine days. There was a single grade 2 complication (readmission with gastric emptying delay) and a single grade 3 complication (bile leak requiring reoperation). Thirty-day mortality was zero and the mean survival was 12 months (with one patient still alive at the time of writing). There were no readmissions with recurrent biliary obstruction or cholangitis. One patient had developed an incisional hernia by the 24-month follow-up appointment.
CONCLUSIONS: HCE in periampullary cancer is safe and effective in selected patients. It involves two simple anastomoses with good access rather than one more demanding anastomosis. Morbidity, patency and overall survival are comparable with contemporary published series of hepaticojejunostomy.

Entities:  

Mesh:

Year:  2012        PMID: 23031763      PMCID: PMC3954240          DOI: 10.1308/003588412X13171221592294

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


Sixty to eighty per cent of patients with periampullary cancer will have unresectable disease due to local invasion or metastases. Currently, most patients are palliated endoscopically but surgical bypass can provide good palliation in cases of failed stenting or when unresectable disease is discovered at the time of surgery (usually after a trial Whipple dissection). Hepaticojejunostomy (usually Roux-en-Y) is the traditional surgical biliary bypass technique. Complication rates and outcome data have been well reported. This anastomosis can be technically demanding and potentially difficult, particularly with bulky periampullary tumours, short fatty jejunal mesentery, and intra-abdominal adiposity resulting in poor visibility and difficult access. This is particularly evident in patients with an elevated body mass index. Other techniques have been reported such as simple cholecystoenterostomy. This is inappropriate if the cystic duct insertion is low (and therefore close to or indeed into the tumour) and can fail because the cystic duct calibre is narrow and can become occluded with debris after the anastomosis has been performed. These shortcomings have led to the technique being largely abandoned in clinical practice. We report an alternative method of surgical biliary bypass using the gallbladder as a conduit. Initially described by Weintraub et al in 1980, in the first reports this technique was used as a secondary procedure when cystic duct obstruction produced recurrent jaundice. Later reports described it as a primary technique when the cystic duct was found to be obstructed at the time of biliary bypass. Eventually, some surgeons advocated it as a primary technique but only 11 cases have been reported and only 6 with outcome data (Table 1).
Table 1

Published literature on hepaticocholecystoenterostomy (HCE)

AuthorsNumber of HCE patientsCystic duct obstructedFollow-up duration
1st operation2nd operation
Weintraub et al, 19804011Not stated
Garnjobst, 198253254–22 months
Browne, 19868Intrahepatic
Koga and Nakayama, 198765004–7 months
Allan and Jackson, 19897511Not stated
Safioleas, 200591008 months
Published literature on hepaticocholecystoenterostomy (HCE) Browne was first to use the term hepaticocholecystojejunostomy for a more complex operation for hilar obstruction but we have used the term hepaticocholecystoenterostomy (HCE) as it describes accurately the use of the in situ gallbladder as a conduit between the common hepatic duct and the small bowel to effect a biliary bypass. We report the results of our experience with HCE and compare these with a contemporary published study of patients undergoing hepaticojejunostomy (Table 2).
Table 2

Hepaticocholecystoenterostomy compared with a published series of hepaticojejunostomy

Our studyn=30Sohn et al (1999)3n=256
Mean age65.5 years64.0 years
Sex19 males (63%)146 males (57%)
Peri-operative mortality0%3.1%
30-day mortality0%3.1%
Mean post-operative length of stay8.6 days10.1 days
Mean operative time147 minutes234 minutes
Reoperation3.4%1%
Leaks3.4%5%
Post-operative cholangitis0%2%
Mean follow-up duration10.2 months8.7 months
Mean survival12 months6.5 months
Hepaticocholecystoenterostomy compared with a published series of hepaticojejunostomy

Technique

Patients with obviously incurable disease are treated usually by endoscopic techniques so most patients having open biliary bypass have undergone a trial dissection for a Whipple procedure. The gallbladder is not mobilised during this phase. If the tumour is unresectable, the gallbladder is assessed for its viability as a conduit. Essential for this purpose are good vascularity with preservation of the cystic artery, pliability without excessive contraction or fibrosis (gallbladder stones do not prevent its use in the bypass per se) and adequate mobility so that a tension free anastomosis can be undertaken to the common hepatic duct. If these criteria are met, the gallbladder is anastomosed to the common hepatic duct usually just above the cystic duct insertion with a single layer of interrupted 4/0 polydioxanone (PDS®; Ethicon, Somerville, NJ, US). The fundus of the gallbladder is then anastomosed to either a Roux-en-Y loop or a simple jejunal loop in two layers using 4/0 PDS®. Both anastomoses are between 1.5cm and 2cm in diameter (Fig 1).
Figure 1

Completed hepaticocholecystoenterostomy

Completed hepaticocholecystoenterostomy

Methods

A prospective operative database identified all patients undergoing a biliary bypass by a single surgeon working in a tertiary hospital in Newcastle, Australia, between 1996 and 2010. Over this 14-year period, 30 of the 129 patients identified underwent HCE. The medical records of these patients were reviewed retrospectively to assess the short-term morbidity and the long-term outcome (particularly anastomotic patency) of HCE. The results of our experience with HCE were then compared with a contemporary published study of patients undergoing a hepaticojejunostomy from another institution.

Results

All 30 patients in this series had a pancreatic adenocarcinoma. Twenty-four patients required a biliary bypass after a failed trial of a Whipple procedure or findings of unexpected metastatic disease and six due to failed endoscopic stenting. There were 19 men and 11 women with a mean age of 65 years. Eight of the thirty patients underwent a primary gastroenterostomy at the time of HCE, and two presented at a later date with gastric outlet obstruction and required this subsequently. Roux-en-Y cholecystojejunostomy was performed in 24 patients and 6 underwent a simple loop cholecystoenterostomy. Operative times ranged from 65 minutes to 270 minutes. The mean operating time was 149 minutes but included a trial Whipple dissection in 24 of the 30 cases. The mean operative time for HCE alone was 92 minutes. The mean length of hospital stay was 9 days (range: 5–17 days). There was a single grade 2 complication (readmission with gastric emptying delay 3 days after initial discharge) and a single grade 3 complication (bile leak requiring reoperation). This occurred at the inferior apex of the hepaticocholecystostomy and was due to excessive tension at this point. At reoperation on day 5, a T-tube was inserted into the leak point to create a controlled biliary fistula. The patient subsequently made an uncomplicated recovery but required a prolonged hospital stay (17 days). Thirty-day mortality was zero. The mean follow-up duration was 10.2 months (range: 1–29 months) with a mean survival of 12 months. There were no readmissions with recurrent biliary obstruction or cholangitis. One patient had developed an incisional hernia identified by the two-year follow-up appointment (Table 3).
Table 3

Operative complications

Age at time of operationSexClavien–Dindo classification10
59 yearsMaleGrade 2 delayed gastric emptying
61 yearsMaleGrade 3 bile leak
68 yearsFemaleIncisional hernia at 2-year follow-up
Operative complications

Discussion

Given that only 20% of pancreatic cancer is resectable at the time of presentation, surgical bypass remains important in palliating patients who have been found at a trial dissection for a Whipple procedure to have unresectable disease. It can also be used in selected patients when endoscopic biliary stenting fails as an alternative to percutaneous transhepatic stent placement. Compared with a standard Roux-en-Y hepaticojejunostomy, which is often difficult in the presence of a bulky periampullary tumour, HCE provides both good access and visibility (to facilitate the anastomoses). It does, however, require two anastomoses and while this may be perceived as a potential disadvantage, both anastomoses are usually easily visible and readily accessible; these anastomoses are therefore relatively easy to perform. The importance of avoiding tension in the anastomosis is highlighted by the single bile leak we report. Improving the utility of this procedure by mobilising the hepatic aspect of the gallbladder may help avoid this problem but does risk devascularising the conduit. The presence of stones in the gallbladder per se does not prevent it being used as a conduit for HCE. Previously, there have been reports of stone formation in the gallbladder when used as a conduit but in our experience it was not problematic in this group of palliative patients.

Conclusions

Our data show that HCE is an effective and durable bypass. (There were no cases of recurrent biliary obstruction.) It is a safe treatment for biliary obstruction with survival and complication rates comparable with hepaticojejunostomy. Hepaticojejunostomy has been the gold standard for biliary bypass and will continue to provide excellent palliation for patients with locally advanced and metastatic periampullary cancer. Nevertheless, we commend the HCE technique to all abdominal surgeons as a simple and easy technique that should appeal to both specialist and non-specialist hepatobiliary surgeons alike.
  11 in total

1.  A new technique for the palliative treatment of high bile duct cancer.

Authors:  Michael C Safioleas
Journal:  Hepatogastroenterology       Date:  2005 Mar-Apr

Review 2.  Biliary tract complications after liver transplantation: a review.

Authors:  Maciej Wojcicki; Piotr Milkiewicz; Michael Silva
Journal:  Dig Surg       Date:  2008-07-15       Impact factor: 2.588

3.  Hepaticocholecystojejunostomy as a simple technique for decompression of the biliary tract.

Authors:  M K Browne
Journal:  Surg Gynecol Obstet       Date:  1986-08

4.  One stage hepaticocholecystojejunostomy as an easy and long term effective bilioenteric bypass for unresectable carcinoma of the pancreas.

Authors:  A Koga; F Nakayama
Journal:  Surg Gynecol Obstet       Date:  1987-08

5.  Hepaticocholecystostomy and cholecystojejunostomy for bile drainage. A palliative procedure.

Authors:  S Weintraub; M Grünspan; D Singer
Journal:  Am J Surg       Date:  1980-03       Impact factor: 2.565

Review 6.  Palliative therapy for pancreatic/biliary cancer.

Authors:  Michael G House; Michael A Choti
Journal:  Surg Clin North Am       Date:  2005-04       Impact factor: 2.741

7.  Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s.

Authors:  T A Sohn; K D Lillemoe; J L Cameron; J J Huang; H A Pitt; C J Yeo
Journal:  J Am Coll Surg       Date:  1999-06       Impact factor: 6.113

8.  Hepatocholecystostomy complemental to palliative cholecystoenterostomy.

Authors:  W Garnjobst
Journal:  Arch Surg       Date:  1982-09

9.  The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.

Authors:  C Verslype; E Van Cutsem; M Dicato; S Cascinu; D Cunningham; E Diaz-Rubio; B Glimelius; D Haller; K Haustermans; V Heinemann; P Hoff; P G Johnston; D Kerr; R Labianca; C Louvet; B Minsky; M Moore; B Nordlinger; S Pedrazzoli; A Roth; M Rothenberg; P Rougier; H-J Schmoll; J Tabernero; M Tempero; C van de Velde; J-L Van Laethem; J Zalcberg
Journal:  Ann Oncol       Date:  2007-06       Impact factor: 32.976

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.